



ST. PAUL'S HOSPITAL OF ILOILO, INC.

General Luna Street, Iloilo City 5000 Philippines

Tel. Nos. (033) 337 2741-49 Fax. No. (033) 338 0676

www.sphi.com.ph sphiloilo@gmail.com

PROTOCOL REPORT UPDATES FORM (SAE/SUSARS Form 4.7)

IRB Protocol No.	<input style="width: 300px; height: 30px;" type="text"/>	Date Received (D/M/Y):	<input style="width: 200px; height: 30px;" type="text"/>
------------------	--	------------------------	--

Protocol Title:	<input style="width: 430px; height: 80px;" type="text"/>	Sponsor:	<input style="width: 200px; height: 50px;" type="text"/>
-----------------	--	----------	--

Principal & Sub Investigators:	<input style="width: 380px; height: 80px;" type="text"/>	Type of SAE	<input type="checkbox"/> SAE <input type="checkbox"/> SUSAR
		Site of SAE	<input type="checkbox"/> On-site <input type="checkbox"/> Off site (International) <input type="checkbox"/> Off site (National)

A: TITLE OF REPORT: _____ **Date of Event:** _____

B. SUMMARY OF SIGNIFICANT DATA:

With Full Document Attachment With Partial Data Attachment

Name of the study medicine/device	Report Date: dd/mm/yyyy IREB Submission Date: dd/mm/yyyy <input type="checkbox"/> Initial <input type="checkbox"/> Follow-up Onset date: dd/mm/yyyy	
Date of first use:		
Patient's Initial/Number:	Age:	<input type="checkbox"/> Male <input type="checkbox"/> Female
Patient's Date of Birth: dd/mm/yyyy	Weight: kg	Height: cm
Relevant medical history and concurrent conditions: 		

I. REACTION INFORMATION:

Check all appropriate to adverse reaction: <input type="checkbox"/> Patient died <input type="checkbox"/> Involved or prolonged inpatient hospitalization <input type="checkbox"/> Involved persistence or significant disability or incapacity	<input type="checkbox"/> Life threatening <input type="checkbox"/> Congenital anomaly
--	--

II. SUSPECT DRUG/S INFORMATION:

Suspect drug/s (include generic name)		Did reaction abate after stopping drug? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA
Daily dose/s:	Route/s of administration:	Did reaction appear after reintroduction? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA
Indication/s for use:		
Therapy date/s: (from/to)	Therapy duration:	
Is this reaction <input type="checkbox"/> Unexpected <input type="checkbox"/> Expected		
Treatment given for Adverse Event:		
Causality Assessment By Investigator (Using WHO-UMC Causality Assessment System) <input type="checkbox"/> Certain <input type="checkbox"/> Probable <input type="checkbox"/> Possible <input type="checkbox"/> Unlikely <input type="checkbox"/> Unclassifiable		
Outcome of reaction/event at the time of last observation: <input type="checkbox"/> Recovered <input type="checkbox"/> Recovering with sequelae <input type="checkbox"/> Death <input type="checkbox"/> Recovering <input type="checkbox"/> Not recovering <input type="checkbox"/> Unknown <input type="checkbox"/>		

INVESTIGATOR'S ATTESTATION

I certify that the information provided in this report is complete and accurate.	
_____	_____
Signature Over Printed Name of Principal Investigator	Date

<i>(IRB Use only)</i> Received by:	
_____	_____
Signature Over Printed Name	Date

SECTION 2: TO BE FILLED UP BY RESPECTIVE IRB MEMBER

Type of Review

Expedited

Full Board

Reviewer's
Comments:

Final Action:

- Request an amendment to the protocol or the consent form.
- Request further information
- Recommend further Action (indicate action)
- Take Note and No Further Action needed
- Others: _____

Acknowledged by:

Name of Reviewer
IRB Member-Secretary

Signature

Date